Pharsight

Omlonti patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8648097 SANTEN Pyridylaminoacetic acid compound
Oct, 2029

(5 years from now)

US10774072 SANTEN Crystal of N-substituted sulfonamide compound
Jun, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685986 SANTEN Medical composition for treatment or prophylaxis of glaucoma
Oct, 2029

(5 years from now)

US11197849 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US10702511 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US9415038 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

USRE48183 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US10179127 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US10765750 SANTEN Pharmaceutical composition containing pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US11666563 SANTEN Pharmaceutical preparation containing pyridyl aminoacetic acid compound
Jul, 2039

(15 years from now)

Omlonti is owned by Santen.

Omlonti contains Omidenepag Isopropyl.

Omlonti has a total of 10 drug patents out of which 0 drug patents have expired.

Omlonti was authorised for market use on 22 September, 2022.

Omlonti is available in solution;ophthalmic dosage forms.

Omlonti can be used as method of treating open-angle glaucoma or ocular hypertension in patients.

Drug patent challenges can be filed against Omlonti from 2026-09-22.

The generics of Omlonti are possible to be released after 16 July, 2039.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 22, 2027

Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient

NCE-1 date: 2026-09-22

Market Authorisation Date: 22 September, 2022

Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

OMLONTI family patents

Family Patents
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11793798 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

Omlonti is owned by Visiox Pharma.

Omlonti contains Omidenepag Isopropyl.

Omlonti has a total of 1 drug patent out of which 0 drug patents have expired.

Omlonti was authorised for market use on 22 September, 2022.

Omlonti is available in solution;ophthalmic dosage forms.

Omlonti can be used as method of treating open-angle glaucoma or ocular hypertension in patients.

Drug patent challenges can be filed against Omlonti from 2026-09-22.

The generics of Omlonti are possible to be released after 08 January, 2035.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 22, 2027

Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient

NCE-1 date: 2026-09-22

Market Authorisation Date: 22 September, 2022

Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

OMLONTI family patents

Family Patents